Urate in Parkinson's Disease: More Than a Biomarker?

Current Neurology and Neuroscience Reports

Volumn 12, Issue 4, 2012, Pages 367-375

  Chen, Xiqun ^a   Wu, Guanhui ^a   Schwarzschild, Michael A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Antioxidant; Biomarker; Clinical trial; Disease modifier; Neurodegeneration; Neurodegenerative diseases; Neuroprotectant; Neuroprotection; Oxidative stress; Parkinson's disease; Purine; Risk factor; Urate

Indexed keywords

BIOLOGICAL MARKER; INOSINE; PLACEBO; URATE;

ARTICLE; CENTRAL NERVOUS SYSTEM; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HEALTH HAZARD; HUMAN; MULTIPLE SCLEROSIS; NEUROPROTECTION; PARKINSON DISEASE; PERIPHERAL NERVOUS SYSTEM; PROGNOSIS; RISK FACTOR; SEX DIFFERENCE; URIC ACID BLOOD LEVEL;

ANIMALS; ANTIOXIDANTS; BIOLOGICAL MARKERS; HUMANS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PARKINSON DISEASE; URIC ACID;

EID: 84865641746     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-012-0282-7     Document Type: Article

References (99)

1. Graham DG. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinines. Mol Pharmacol. 1978;14:633-43. (Pubitemid 8402469)
2. Tse DC, McCreery RL, Adams RN. Potential oxidative pathways of brain catecholamines. J Med Chem. 1976;19:37-40.
3. Adams RN, Murrill E, McCreery R, et al. 6-hydroxy-dopamine, a new oxidation mechanism. Eur J Pharmacol. 1972;17:287-92.
4. Youdim MB, Ben Shachar D, Riederer P. Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurogeneration? Acta Neurol Scand Suppl. 1989;126:47-54. (Pubitemid 20022076)
5. Surmeier DJ, Guzman JN, Sanchez-Padilla J, et al. The origins of oxidant stress in Parkinson's disease and therapeutic strategies. Antioxid Redox Signal. 2011;14(7):1289-301.
6. Guzman JN, Sanchez-Padilla J, Wokosin D, Kondapalli J, et al. Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature. 2010;468(7324):696-700.
7. Mosharov EV, Larsen KE, Kanter E, et al. Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron. 2009;62(2):218-29.
8. Tsang AH, Chung KK. Oxidative and nitrosative stress in Parkinson's disease. Biochim Biophys Acta. 2009;1792(7):643-50.
9. Alam ZI, Jenner A, Daniel SE, et al. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem. 1997;69:1196-203. (Pubitemid 27364841)
10. Dexter DT, Holley AE, Flitter WD, et al. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov Disord. 1994;9:92-7. (Pubitemid 24022621)
11. Dexter DT, Sian J, Rose S, et al. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol. 1994;35:38-44. (Pubitemid 24027604)
12. Henchcliffe C, Beal MF. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol. 2008;4(11):600-9.
13. Hart RG, Pearce LA, Ravina BM, et al. Neuroprotection trials in Parkinson's disease: systematic review. Mov Disord. 2009;24 (5):647-54.
14. Olanow CW, Kieburtz K, Schapira AH. Why have we failed to achieve neuroprotection in Parkinson's disease? Ann Neurol. 2008;64 Suppl 2:S101-10.
15. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayedstart trial of rasagiline in Parkinson's disease. N Engl J Med. 2009;361(13):1268-78.
16. Ahlskog JE, Uitti RJ. Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction? Neurology. 2010;74 (14):1143-8.
17. National Institute of Neurological Disorders and Stroke: Statement on the Termination of QE3 Study. Available at http://www.ninds. nih.gov/disorders/ clinical-trials/CoQ10-Trial-Update.htm.
18. Hung AY, Schwarzschild M.A. Clinical trials for neuroprotection in Parkinson's disease: overcoming angst and futility? Curr Opin Neurol. 2007;20(4):477-83. (Pubitemid 47051997)
19. Ravina BM, Fagan SC, Hart RG, et al. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology. 2003;60(8):1234-40. (Pubitemid 36460976)
20. Morelli M, Carta AR, Kachroo A, et al. Pathophysiological roles for purines: adenosine, caffeine and urate. Prog Brain Res. 2010;183:183-208.
21. Quik M, Huang LZ, Parameswaran N, et al. Multiple roles for nicotine in Parkinson's disease. Biochem Pharmacol. 2009;78 (7):677-85.
22. Ames BN, Cathcart R, Schwiers E, et al. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A. 1981;78 (11):6858-62. (Pubitemid 12216861)
23. Davies KJ, Sevanian A, Muakkassah-Kelly SF, et al. Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid. Biochem J. 1986;235(3):747-54.
24. Hink HU, Santanam N, Dikalov S, et al. Peroxidase properties of extracellular superoxide dismutase: role of uric acid in modulating in vivo activity. Arterioscler Thromb Vasc Biol. 2002;22(9):1402-8.
25. Sevanian A, Davies KJ, Hochstein P. Conservation of vitamin C by uric acid in blood. J Free Radic Biol Med. 1985;1(2):117-24. (Pubitemid 16133248)
26. Kuzkaya N, Weissmann N, Harrison DG, et al. Interactions of peroxynitrite with uric acid in the presence of ascorbate and thiols: implications for uncoupling endothelial nitric oxide synthase. Biochem Pharmacol. 2005;70(3):343-54. (Pubitemid 40905106)
27. Whiteman M, Halliwell B. Protection against peroxynitritedependent tyrosine nitration and alpha 1-antiproteinase inactivation by ascorbic acid. A comparison with other biological antioxidants. Free Radic Res. 1996;25(3):275-83.
28. Yeum KJ, Russell RM, Krinsky NI, et al. Biomarkers of antioxidant capacity in the hydrophilic and lipophilic compartments of human plasma. Arch Biochem Biophys. 2004;430(1):97-103. (Pubitemid 39119784)
29. Proctor P. Similar functions of uric acid and ascorbate in man? Nature. 1970;228(5274):868.
30. Hershfield MS, Roberts 2nd LJ, Ganson NJ, et al. Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo. Proc Natl Acad Sci U S A. 2010;107(32):14351-6.
31. Waring WS, Webb DJ, Maxwell SR. Systemic uric acid administration increases serum antioxidant capacity in healthy volunteers. J Cardiovasc Pharmacol. 2001;38(3):365-71. (Pubitemid 32769556)
32. Amaro S, Chamorro Á. Translational stroke research of the combination of thrombolysis and antioxidant therapy. Stroke. 2011;42 (5):1495-9.
33. Scott GS, Hooper DC. The role of uric acid in protection against peroxynitrite-mediated pathology. Med Hypotheses. 2001;56:95-100. (Pubitemid 32052828)
34. O'Neill RD, Lowry JP. On the significance of brain extracellular uric acid detected with in-vivo monitoring techniques: a review. Behav Brain Res. 1995;71(1-2):33-49.
35. Church WH, Ward VL. Uric acid is reduced in the substantia nigra in Parkinson's disease: effect on dopamine oxidation. Brain Res Bull. 1994;33(4):419-25.
36. Larumbe Ilundain R, Ferrer Valls JV, Vines Rueda JJ, et al. Case-control study of markers of oxidative stress and metabolism of blood iron in Parkinson's disease. Rev Esp Salud Publica. 2001;75 (1):43-53. (Pubitemid 32487905)
37. Annanmaki T, Muuronen A, Murros K. Low plasma uric acid level in Parkinson's disease. Mov Disord. 2007;22(8):1133-7. (Pubitemid 47067223)
38. Andreadou E, Nikolaou C, Gournaras F, et al. Serum uric acid levels in patients with Parkinson's disease: their relationship to treatment and disease duration. Clin Neurol Neurosurg. 2009;111 (9):724-8.
39. Bogdanov M, Matson WR, Wang L, et al. Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain. 2008;131(Pt. 2):389-96. (Pubitemid 351197614)
40. Sun C, Luo F, Wei L, et al. Association of serum uric acid levels with the progression of Parkinson's disease in Chinese patients. Chin Med J. 2012;125(4):583-7.
41. Tohgi H, Abe T, Takahashi S, et al. The urate and xanthine concentrations in the cerebrospinal fluid in patients with vascular dementia of the Binswanger type, Alzheimer type dementia, and Parkinson's disease. J Neural Transm Park Dis Demet Sect. 1993;6 (2):119-26. (Pubitemid 24014258)
42. Maetzler W, Stapf AK, Schulte C, Hauser AK, et al. Serum and cerebrospinal fluid uric acid levels in lewy body disorders: associations with disease occurrence and amyloid-? pathway. J Alzheimers Dis. 2011;27(1):119-26.
43. Davis JW, Grandinetti A, Waslien CI, et al. Observations on serum uric acid levels and the risk of idiopathic Parkinson's disease. Am J Epidemiol. 1996;144(5):480-4. (Pubitemid 26296131)
44. de Lau LM, Koudstaal PJ, Hofman A, et al. Serum uric acid levels and the risk of Parkinson disease. Ann Neurol. 2005;58(5):797-800. (Pubitemid 41552559)
45. Weisskopf MG, O'Reilly E, Chen H, et al. Plasma urate and risk of Parkinson's disease. Am J Epidemiol. 2007;166 (5):561-7. (Pubitemid 47283643)
46. Chen H, Mosley TH, Alonso A, et al. Plasma urate and Parkinson's disease in the Atherosclerosis Risk In Communities (ARIC) study. Am J Epidemiol. 2009;169(9):1064-9.
47. Winquist A, Steenland K, Shankar A. Higher serum uric acid associated with decreased Parkinson's disease prevalence in a large community-based survey. Mov Disord. 2010;25(7):932-6.
48. Jain S, Ton TG, Boudreau RM, et al. The risk of Parkinson disease associated with urate in a community-based cohort of older adults. Neuroepidemiology. 2011;36(4):223-9.
49. Gao X, Chen H, Choi HK, et al. Diet, urate, and Parkinson's disease risk in men. Am J Epidemiol. 2008;167(7):831-8. (Pubitemid 351451751)
50. Alonso A, Rodriguez LA, Logroscino G, et al. Gout and risk of Parkinson disease: a prospective study. Neurology. 2007;69 (17):1696-700. (Pubitemid 350287126)
51. De Vera M, Rahman MM, Rankin J, et al. Gout and the risk of Parkinson's disease: a cohort study. Arthritis Rheum. 2008;59 (11):1549-54.
52. Facheris MF, Hicks AA, Minelli C, et al. Variation in the uric acid transporter gene SLC2A9 and its association with AAO of Parkinson's disease. J Mol Neurosci. 2011;43(3):246
53. O'Reilly EJ, Gao X, Weisskopf MG, et al. Plasma urate and Parkinson's disease in women. Am J Epidemiol. 2010;172 (6):666-70.
54. Ascherio A, LeWitt PA, Xu K, et al. Urate predicts rate of clinical decline in Parkinson disease. Arch Neurol. 2009;66(12):1460-8.
55. Schwarzschild MA, Schwid SR, Marek K, et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol. 2008;65(6):716-23. (Pubitemid 351831449)
56. Schwarzschild MA, Marek K, Eberly S, et al. Serum urate and probability of dopaminergic deficit in early "Parkinson's disease". Mov Disord. 2011;26(10):1864-8.
57. Annanmaki T, Pessala-Driver A, Hokkanen L, et al. Uric acid associates with cognition in Parkinson's disease. Parkinsonism Relat Disord. 2008;14(7):576-8.
58. Wang XJ, Luo WF, Wang LJ, et al. Study on uric acid and the related factors associated with cognition in the patients with Parkinson's disease. Chin Med J. 2009;89(23):1633-5.
59. Annanmaki T, Pohja M, Parviainen T, et al. Uric acid and cognition in Parkinson's disease: a follow-up study. Parkinsonism Relat Disord. 2011;17(5):333-7.
60. Euser SM, Hofman A, Westendorp RGJ, et al. Serum uric acid and cognitive function and dementia. Brain. 2009;132:377-82.
61. Maetzler W, Stapf AK, Schulte C, et al. Serum and cerebrospinal fluid uric acid levels in lewy body disorders: associations with disease occurrence and amyloid-? pathway. J Alzheimers Dis. 2011;27(1):119-26.
62. Maesaka JK, Wolf-Klein G, Piccione JM, et al. Hypouricemia, abnormal renal tubular urate transport, and plasma natriuretic factor(s) in patients with Alzheimer's disease. J Am Geriatr Soc. 1993;41(5):501-6. (Pubitemid 23135890)
63. Rinaldi P, Polidori MC, Metastasio A, et al. Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. Neurobiol Aging. 2003;24(7):915-9. (Pubitemid 36962976)
64. Polidori MC, Mattioli P, Aldred S, et al. Plasma antioxidant status, immunoglobulin g oxidation and lipid peroxidation in demented patients: relevance to Alzheimer disease and vascular dementia. Dement Geriatr Cogn Disord. 2004;18(3-4):265-70. (Pubitemid 39370302)
65. Beal MF, Matson WR, Storey E, et al. Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex. J Neurol Sci. 1992;108(1):80-7.
66. Zoccolella S, Simone IL, Capozzo R, et al. An exploratory study of serum urate levels in patients with amyotrophic lateral sclerosis. J Neurol. 2011;258:238-43.
67. Keizman D, Ish-Shalom M, Berliner S, et al. Low uric acid levels in serum of patients with ALS: further evidence for oxidative stress? J Neurol Sci. 2009;285:95-9.
68. Auinger P, Kieburtz K, McDermott MP. The relationship between uric acid levels and Huntington's disease progression. Mov Disord. 2010;25(2):224-8.
69. Paganoni S, Zhang M, Quiroz Zárate A, et al. Uric acid levels predict survival in men with amyotrophic lateral sclerosis. J Neurol. 2012 Feb 10.
70. Irizarry MC, Raman R, Schwarzschild MA, et al. Plasma urate and progression of mild cognitive impairment. Neurodegener Dis. 2009;6(1-2):23-8.
71. Logallo N, Naess H, Idicula TT, et al. Serum uri acid: neuroprotection in thrombolysis. The Bergen NORSTROKE study. BMC Neurol. 2011;11:114.
72. Yu ZF, Bruce-Keller AJ, Goodman Y, et al. Uric acid protects neurons against excitotoxic and metabolic insults in cell culture and against focal ischemic brain injury in vivo. J Neurosci Res. 1998;53(5):613-25. (Pubitemid 28380802)
73. Romanos E, Planas AM, Amaro S, et al. Uric acid reduces brain damage and improves the benefits of rt-PA in a rat model of thromboembolic stroke. J Cereb Blood Flow Metab. 2007;27 (1):14-20. (Pubitemid 46006580)
74. Chen P, Goldberg DE, Kolb B, et al. Inosine induces axonal rewiring and improves behavorial outcome after stroke. Proc Natl Acad Sci USA. 2002;99(13):9031-6. (Pubitemid 34693678)
75. Shen H, Chen GJ, Harvey BK, et al. Inosine reduces ischemic brain injury in rats. Stroke. 2005;36:654-9. (Pubitemid 40344173)
76. Hooper CD, Bagasra O, Marini JC, et al. Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite: implications for the treatment of multiple sclerosis. Proc Natl Acad Sci. 1997;94:2528-33. (Pubitemid 27136909)
77. Hooper DC, Spitsin S, Kean RB, et al. Uric acid, a natural scavenger of peroxynitrite in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci. 1998;95:675-80. (Pubitemid 28083802)
78. Scott GS, Spitsin SV, Kean RB, et al. Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors. Proc Natl Acad Sci. 2002;99(25):16303-8. (Pubitemid 35462790)
79. Du Y, Chen CP, Tseng CY, et al. Astroglia-mediated effects of uric acid to protect spinal cord neurons from glutamate toxicity. Glia. 2007;55(5):463-72. (Pubitemid 46383176)
80. Scott GS, Cuzzocrea S, Genovese T, et al. Uric acid protects against secondary damage after spinal cord injury. Proc Natl Acad Sci. 2005;102(9):3483-8. (Pubitemid 40328071)
81. Aoyama K, Matsumura N, Watabe M, et al. Caffeine and uric acid mediate glutathione synthesis for neuroprotection. Neuroscience. 2011;181:206-15.
82. Serra PA, Sciola L, Delogu MR, et al. The neurotoxin 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine(MPTP) induces apoptosis in mouse nigrostriatal glia. Relevance to nigral neuronal death and striatal neurochemical changes. J Biol Chem. 2002;277 (37):34451-61.
83. Desole MS, Esposito G, Fresu L, et al. Further investigation of allopurinol effects on MPTP-induced oxidative stress in the striatum and brain stem of the rat. Pharmacol Biochem Behav. 1996;54 (2):377-83. (Pubitemid 26180173)
84. Church WH, Fong YT. Changes in uric acid during acute infusion of MPP+, 6-OHDA, and FeCl3. A microdialysis studying the substantia nigra of the guinea pig. Mol Chem Neurpathol. 1996;27(2):131-44.
85. Moor E, Shohami E, Kanevsky E, et al. Impairment of the ability of the injured aged brain in elevating urate and ascorbate. Exp Gerontol. 2006;41(3):303-11.
86. Jones DC, Gunasekar PG, Borowitz JL, et al. Dopamine induced apoptosis is mediated by oxidative stess and is enhanced by cyanide in differentiated PC12 cells. J Neurochem. 2000;74(6):2296-304. (Pubitemid 30314204)
87. Zhu TG, Wang XX, Luo WF, et al. Protective effects of urate against 6-OHDA-induced cell injury in PC12 cells through antioxidant action. Neurosci Lett. 2012;506(2):175-9.
88. Duan W, Ladenheim B, Cutler RG, et al. Dietary folate deficiency and elevated homoocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J Neurchem. 2002;80 (1):101-10. (Pubitemid 34614582)
89. Guerreiro S, Ponceau A, Toulorge D, et al. Protection of midbrain dopaminergic neurons by the end-product of purine metabolism uric acid: potentiation by low-level depolarization. J Neurochem. 2009;109(4):1118-28.
90. Wang LJ, Luo WF, Wang HH, et al. Protective effects of uric acid on nigrostriatal system injury induced by 6-hydroxydopamine in rats. [Article in Chinese]. Zhonghua Yi Xue Za Zhi. 2010;90 (19):1362-5.
91. Cipriani S, Desjardins CA, Burdett TC, et al. Protective effect of urate on a dopaminergic cell line is potentiated by astrocytes (abstract 858.29). Presented at the annual meeting of Society of Neuroscience. San Diego, CA, Nov 12-17, 2010.
92. Cipriani S, Desjardins CA, Burdett TC, et al. Urate protects midbrain dopaminergic neurons from MPP+?induced toxicity (52.05). Presented at the annual meeting of Society of Neuroscience. Washington, DC, Nov 11-16, 2011.
93. Chen X, Desjardins CA, Burdett T, et al. Effects of urate oxidase transgene or knockout on 6-ohda neurotoxicity. Presented at the annual meeting of Society of Neuroscience. Washington, DC, Nov 11-16, 2011.
94. The Parkinson Study Group: Safety of Urate Elevation in Parkinson's Disease (SURE-PD). Available at http://clinicaltrials.gov/ct2/show/NCT00833690. Accessed September 2010.
95. Álvarez-Lario B, Macarrón-Vicente J. Uric acid and evolution. Rheumatology (Oxford). 2010;49(11):2010-5.
96. Kutzing MK, Firestein BL. Altered uric acid levels and disease states. J Pharmacol Exp Ther. 2008;324(1):1-7. (Pubitemid 350294141)
97. Goldman L, Caldera DL, Nussbaum S.R. Multifactorial index of cardiac risk in noncardiac surgical procedures. N Engl J Med. 1977;297:845-50. (Pubitemid 8200494)
98. Schlossmacher MG, Mollenhauer B. Biomarker research in Parkinson's disease: objective measures needed for patient stratification in future cause-directed trials. Biomark Med. 2010;4(5):647-50.
99. Cipriani S, Chen X, Schwarzschild M.A. Urate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis. Biomark Med. 2010;4(5):701-12.